Recent developments in malaria vaccinology.
The development of a highly effective malaria vaccine remains a key goal to aid in the control and eventual eradication of this devastating parasitic disease. The field has made huge strides in recent years, with the first-generation vaccine RTS,S showing modest efficacy in a Phase III clinical trial. The updated 2030 Malaria Vaccine Technology Roadmap calls for a second generation vaccine to achieve 75% efficacy over two years for both Plasmodium falciparum and Plasmodium vivax, and for a vaccine that can prevent malaria transmission. Whole-parasite immunisation approaches and combinations of pre-erythrocytic subunit vaccines are now reporting high-level efficacy, whilst exciting new approaches to the development of blood-stage and transmission-blocking vaccine subunit components are entering clinical development. The development of a highly effective multi-component multi-stage subunit vaccine now appears to be a realistic ambition. This review will cover these recent developments in malaria vaccinology.
The Jenner Institute, University of Oxford, Oxford, UK.
Benedict R
BR
Halbroth
The Jenner Institute, University of Oxford, Oxford, UK.
Simon J
SJ
Draper
D000818:Animals; D006801:Humans; D007114:Immunization / Q000639:trends*; D008288:Malaria / Q000517:prevention & control; D017780:Malaria Vaccines / Q000276:immunology* / Q000592:standards*; D034101:Sporozoites / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology
D017780:Malaria Vaccines; D022223:Vaccines, Subunit
Adjuvant; Blood-stage; Liver-stage; Malaria; Plasmodium; Sporozoite; Transmission-blocking; Vaccine